Let's look beyond the hype the company is generating this year.Could 2024 be a breakout year for Viking Therapeutics (VKTX -4.01%)? The mid-cap biotech has generated more positive headlines than most of its peers. Excitement is through the roof. Due to crucial clinical progress, Viking Therapeutics' shares have tripled this year.Biotech investors have noticed, but many remain on the sidelines wondering whether Viking is the right choice for them -- or whether the stock is a one-hit (or one-year) wonder. Let ...

Viking's stock has tripled in less than a year, and its red-hot valuation could have investors thinking twice about buying it today.Viking Therapeutics (VKTX 7.09%) has been one of the hottest healthcare stocks to own this year, thanks to hype and excitement relating to its promising weight loss treatment, VK2735. The potential that investors see in the drug is a key reason the stock has ballooned to a market cap of nearly $6 billion despite the company generating no revenue and having no approved products ...

Sasha Brazhnik/iStock via Getty Images The weight loss drug sector is seeing an increasingly intensified drug development focus, causing a small player like Viking Therapeutics, Inc. (NASDAQ:VKTX) to slip. The small biotech has had some promising drug results, but the fear is the need to find a partner for GLP-1 manufacturing while additional drugs on the market could lead to pricing compression. My investment thesis is Bullish on Viking Therapeutics, especially with the gap closed down at $40. Source ...

Viking Therapeutics (VKTX) has been attracting investor interest for quite a while, all thanks to the rapid progress of its pipeline candidates targeting obesity and non-alcoholic steatohepatitis (NASH) indications.This year, management reported encouraging results on its obesity and NASH drug programs. These results position the company’s pipeline candidates strongly against currently available therapies targeting these diseases.So far this year, the stock has surged 197.3% against the industry’s 6.3% decl ...

It's a tough act to follow.Few biotech companies have made more noise than Viking Therapeutics (VKTX 4.41%) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the industry. However, Viking's prominence and stock price soared thanks to excellent clinical progress. The biotech's shares are up by 154% since early January.Can Viking Therapeutics perform nearly as well during the second half of the year? Is it already too late to buy the stock? Let's find out. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other juris ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 EarninConference Call April 24, 2024 8:30 AM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Joon Lee - Truist Kambiz Yazdi - Jefferies Annabel Samimy - Stifel Jay Olson - Oppenheimer Andrew Hsieh - William Blair Nick Econom - Raymond James Thomas Smith - Leerink Partners Yale Jen - Laidlaw & Co Justin Zelin - BTIG Operator ...

Exhibit 99.1 Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-Adjusted Weight Loss (14.7% From Baseline) at 13 Weeks; Shown to be Safe and Well-Tolerated • Results From Phase 1 Trial of Oral VK2735 Demonstrated Promising Safety and Tolerability With Up to 3.3% Placebo-Adjusted Weight Loss (5.3% From Baselin ...

Start Time: 08:30 January 1, 0000 9:18 AM ET Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2023 Earnings Conference Call February 07, 2024, 16:30 PM ET Company Participants Brian Lian - President and CEO Greg Zante - CFO Stephanie Diaz - Manager of IR Conference Call Participants Joon Lee - Truist Steven Seedhouse - Raymond James Jay Olson - Oppenheimer. Naz Rahman - Maxim Group. Andy Hsieh - William Blair. Thomas Smith - Leerink Partners. Yale Jen - Laidlaw & Company. Joe Pantginis - HC Wainwright. Jack Padov ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 46-1073877 ( State or other jurisdict ...